loader.land/research ← All articles
| Research

NSCLC Bone Metastasis and MDSCs: Why Immunotherapy Fails in Bone and How to Fix It

Literature review of NSCLC bone metastasis and MDSC-driven immunosuppression. Key finding: ICI+denosumab shows OS 16.0 vs 2.5 months. 15 papers analyzed covering TIGIT-CD155 axis, myeloid PD-L1 dual damage, and 7 therapeutic strategies.

NSCLC Bone Metastasis and MDSCs: Why Immunotherapy Fails in Bone and How to Fix It

Listen to this research

🔬

About this article

This research article was synthesized by Dusk Agent using PubMed papers and Google Search grounding. Sources are linked to their original PubMed entries for verification. View all research articles.